OncoMatch/Clinical Trials/NCT04267848
Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])
Is NCT04267848 recruiting? Yes, currently enrolling (May 2026). This Phase 3 trial studies multiple treatments for lung non-small cell carcinoma.
Treatment: Carboplatin · Cisplatin · Gemcitabine Hydrochloride · Paclitaxel · Pembrolizumab · Pemetrexed Disodium — This phase III ALCHEMIST treatment trial tests the addition of pembrolizumab to usual chemotherapy for the treatment of stage IIA, IIB, IIIA or IIIB non-small cell lung cancer that has been removed by surgery. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Chemotherapy drugs, such as cisplatin, pemetrexed, carboplatin, gemcitabine hydrochloride, and paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving pembrolizumab with usual chemotherapy may help increase survival times in patients with stage IIA, IIB, IIIA or IIIB non-small cell lung cancer.
Check if I qualifyExtracted eligibility criteria
Cancer type
Non-Small Cell Lung Carcinoma
Biomarker criteria
Required: ALK wild-type
Required: PD-L1 (CD274) any tested (testing required; no eligibility threshold specified)
Required: EGFR wild-type
Disease stage
Required: Stage IIA, IIB, IIIA, IIIB (T3-4N2)
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Cannot have received: neoadjuvant therapy
No prior neoadjuvant or adjuvant therapy for current lung cancer diagnosis
Cannot have received: adjuvant therapy
No prior neoadjuvant or adjuvant therapy for current lung cancer diagnosis
Cannot have received: allogeneic tissue/solid organ transplant
No prior allogeneic tissue/solid organ transplant
Lab requirements
Blood counts
Absolute neutrophil count (ANC) >= 1,500/mm^3; Platelet count >= 100,000/mm^3; Hemoglobin >= 8 gm/dl
Kidney function
Calculated (Calc.) creatinine clearance >= 45 mL/min
Liver function
Total bilirubin <= 1.5 x upper limit of normal (ULN); AST/ALT <= 2.5 x ULN
Absolute neutrophil count (ANC) >= 1,500/mm^3; Platelet count >= 100,000/mm^3; Hemoglobin >= 8 gm/dl; Calculated (Calc.) creatinine clearance >= 45 mL/min; Total bilirubin <= 1.5 x upper limit of normal (ULN); Aspartate aminotransferase (AST) / alanine aminotransferase (ALT) <= 2.5 x upper limit of normal (ULN)
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Anchorage Associates in Radiation Medicine · Anchorage, Alaska
- Anchorage Radiation Therapy Center · Anchorage, Alaska
- Alaska Breast Care and Surgery LLC · Anchorage, Alaska
- Alaska Oncology and Hematology LLC · Anchorage, Alaska
- Alaska Women's Cancer Care · Anchorage, Alaska
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify